David Holtzman: Attacking Alzheimer's With a New Test for Amyloid Beta
His SILK test quickly reveals whether medication is working to limit the harmful protein amyloid beta
Posted June 30, 2009
David Holtzman, Neurologist, Washington University Medical School (Jeffrey MacMillan for USN&WR)